Samsara BioCapital

Samsara BioCapital is a venture capital firm founded in 2016, dedicated to investing in early-stage life sciences companies. The firm focuses on sectors such as biotechnology, healthcare, and digital health, aiming to support transformative innovations that improve patient outcomes and advance medical research. Samsara BioCapital provides capital, expertise, and strategic guidance to help portfolio companies succeed, emphasizing a collaborative, hands-on approach. The firm's investment team comprises scientists, investors, and operators who apply a rigorous diligence process to each investment opportunity, operating with high ethics and integrity. Samsara BioCapital's portfolio includes companies like Abcuro, Inc., A2 Biotherapeutics, Abivax, Abata Therapeutics, and Allakos, Inc., among others. The firm is headquartered in Palo Alto, California, and has a global investment presence, including in the United States, United Kingdom, Canada, France, China, Germany, Switzerland, and Denmark. Samsara BioCapital's investment stages range from Seed to Post-IPO Equity, with investment sizes typically between $500,000 and $5 million. The firm's mission is to empower entrepreneurs in the biotechnology and healthcare sectors by providing the resources and support needed to bring innovative therapies to market, ultimately aiming to transform the future of biotechnology and healthcare by supporting the next generation of scientific breakthroughs.